Use of purpurogallin and glycosides thereof in treating ischemia in mammals
US5248668A · kind A · utility
5Cited by
2References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 28, 1992 |
| Grant date | Sep 28, 1993 |
| Priority date | — |
| Expiry date | Sep 28, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Purpurogallin and its mono- and di-glucosides are useful as cytoprotective agents. Patient-administrable compositions for addition to a patient's blood to minimize oxyradical damage caused by ischemia-reperfusion injury that may result in various surgical procedures, and comprising purpurogallin or glucosides thereof, and uses thereof, are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.